Sanofi India Ltd
NSE:SANOFI

Watchlist Manager
Sanofi India Ltd Logo
Sanofi India Ltd
NSE:SANOFI
Watchlist
Price: 6 064 INR -3.33% Market Closed
Market Cap: 139.7B INR

SANOFI's latest stock split occurred on Sep 23, 1994

The company executed a 2-for-1 stock split, meaning that for every share held, investors received 2 new shares.

The adjusted shares began trading on Sep 23, 1994. This was SANOFI's 2nd stock split, following the previous one in Nov 18, 1991.

Last Splits:
Sep 23, 1994
2-for-1
Nov 18, 1991
100-for-10
Pre-Split Price
N/A
Post-Split Price
1 840.4707
Before
After
Last Splits:
Sep 23, 1994
2-for-1
Nov 18, 1991
100-for-10

Sanofi India Ltd
Stock Splits History

SANOFI Stock Splits Timeline
Sep 23, 1994
Sep 23, 1994
Split 2-for-1
x2
Pre-Split Price
N/A
Post-Split Price
1 840.4707
Before
After
Nov 18, 1991
Nov 18, 1991
Split 100-for-10
x10
Pre-Split Price
N/A
Post-Split Price
1 840.4707
Before
After

Global
Stock Splits Monitor

Date Company Split Pre-Split Price Post-Split Price
Apr 22, 2025
Seres Therapeutics Inc
SWB:1S9
1-for-20
/20
0.3216 6.432 EUR 6.432 6.432 EUR
Apr 22, 2025
G
Golden Shield Resources Inc
F:4LE0
1-for-10
/10
0.011 0.11 EUR 0.11 0.11 EUR
Apr 22, 2025
E
EV Advanced Material Co Ltd
KOSDAQ:131400
911-for-787
x1.1575603557814
1493 1493 KRW 1439 1439 KRW
Apr 22, 2025
Seres Therapeutics Inc
F:1S9
1-for-20
/20
0.01 0.2 EUR 0.2 0.2 EUR
Apr 22, 2025
G
Golden Shield Resources Inc
OTC:GSRFF
1-for-10
/10
0.024 0.24 USD 0.24 0.24 USD
Load More

Sanofi India Ltd
Glance View

Market Cap
139.7B INR
Industry
Pharmaceuticals

Sanofi India Ltd., a prominent name in the pharmaceutical landscape, operates as a subsidiary of Sanofi S.A., the global healthcare giant headquartered in France. Its roots in India trace back to the early 1950s when it began importing and distributing vaccines. Over the decades, Sanofi India has evolved into a comprehensive provider of high-quality drugs, contributing significantly to the nation’s healthcare ecosystem. The company focuses primarily on therapeutic segments such as diabetes, cardiovascular diseases, oncology, and vaccines, boasting a robust portfolio of prescription medicines and over-the-counter products. By leveraging a vast network of healthcare professionals and engaging in continuous clinical research and development, Sanofi India ensures its position at the forefront of medical innovation, adhering to a global strategy of patient-oriented solutions and a commitment to improving health outcomes. Sanofi India's revenue model revolves around its diversified product portfolio, addressing a spectrum of critical health areas. The company generates income through the sale of its flagship products, which include insulin for diabetes management, anti-allergy medications, and innovative therapies for rare diseases, among others. While the domestic market plays a crucial role in its financial framework, Sanofi India also taps into international markets, exporting its high-quality pharmaceutical products across borders. The profitability of the company is further bolstered by its commitment to research and development, enabling it to introduce new drugs and therapies, thus continually expanding its market share. By maintaining strong distribution channels and fostering collaborations with medical institutions and regulatory bodies, Sanofi India ensures its products reach a broad consumer base, perpetuating its growth trajectory in the competitive pharmaceutical scene.

SANOFI Intrinsic Value
3 175.8 INR
Overvaluation 48%
Intrinsic Value
Price
Back to Top